It is therefore possible that inhibition of ERAP1, by generating a novel immunopeptidome, may be a viable therapeutic strategy to enhance anti-tumor immune responses in non-immunogenic tumors, such as NB, in combination with a treatment that enhances the surface expression of MHC class I molecules. This evidence concerns the gene ERAP1 and neoplasm.